Results 61 to 70 of about 1,333,557 (170)

Discontinuation of Eculizumab treatment after hematological remission in patients with atypical and drug-induced hemolytic uremic syndrome

open access: yesRomanian Journal of Internal Medicine, 2022
Introduction. The aim was to evaluate the effect of therapeutic plasma exchange (TPE) and eculizumab on hematological and renal survival in atypical hemolytic uremic syndrome (aHUS), and additionally, to examine the reliability of discontinuation of ...
Yeter Hasan H.   +5 more
doaj   +1 more source

Iron and Other Metal Ions in Human Health and Disease

open access: yesMedComm, Volume 7, Issue 10, October 2026.
Iron, copper, zinc, and calcium orchestrate cellular function through distinct yet cooperative mechanisms: redox‐active iron and copper cycle between oxidation states to act as Fenton catalysts and electron carriers in oxidative phosphorylation (OXPHOS); redox‐inert zinc serves as a structural component of zinc‐finger proteins and a catalytic cofactor ...
Xiaofeng Dai, Jitian Li
wiley   +1 more source

Pancreatitis and Myocardial Infarction as Complications of Thrombotic Thrombocytopenic Purpura: A Case Report

open access: yesClinical Case Reports, Volume 14, Issue 9, September 2026.
ABSTRACT Thrombotic thrombocytopenic purpura (TTP) is a rare disease with a mortality rate of 90% if not treated promptly. Due to limited clinical experience and sometimes atypical presentation, early detection of TTP is not always easy. The pathophysiological mechanisms underlying TTP can accelerate thrombus formation and vascular occlusion ...
Farid Poursadegh   +3 more
wiley   +1 more source

Multiplex PCR to Diagnose Gastrointestinal Infections: Key Limitations in Interpretation

open access: yesUnited European Gastroenterology Journal, Volume 14, Issue 7, September 2026.
ABSTRACT Multiplex polymerase chain reaction (PCR) panels are increasingly used for the evaluation of acute diarrhea, providing rapid and sensitive detection of a broad range of enteric pathogens. However, their widespread adoption has created important interpretive challenges for clinicians.
Giannoula S. Tansarli, Ferric C. Fang
wiley   +1 more source

Multiple Myeloma as the Underlying Cause of Thrombotic Microangiopathy Leading to Acute Kidney Injury: Revisiting a Very Rare Entity

open access: yesJournal of Investigative Medicine High Impact Case Reports, 2017
Thrombotic microangiopathy (TMA) describes a pathological process of microvascular thrombosis, consumptive thrombocytopenia, and microangiopathic hemolytic anemia, leading to end-organ ischemia and infarction, affecting particularly the kidney and brain.
Savneek Chugh MD   +4 more
doaj   +1 more source

Use of eculizumab in pregnancy-associated atypical hemolytic uremic syndrome

open access: yes, 2018
Pregnancy-associated atypical hemolytic uremic syndrome (p-aHUS) is a rare disorder, with an estimated incidence of 1 in 25,000 pregnancies [Fakhouri F, Roumenina L, Provot F, Sallee M, Caillard S, Couzi L, et al.
Lawrence D. Platt   +4 more
core   +1 more source

Clinical case of thrombotic microangiopathy in obstetric practice

open access: yesСеченовский вестник, 2017
Trombotic microangiopathy is heterogeneous group of the diseases united by a community of a histological and clinical implications at difference of pathogenetic mechanisms, presents clinical-morphological syndrome characterizing a lesion of vessels of a ...
M. N. Mochalova   +5 more
doaj  

A Case of Carfilzomib-Induced Atypical Hemolytic Uremic Syndrome

open access: yesAnnals of Internal Medicine: Clinical Cases
Atypical hemolytic uremic syndrome (aHUS) is a rare non-Shiga toxin thrombotic microangiopathy caused by uncontrolled activation of the alternative complement pathway.
Kwasi Opare-Addo   +3 more
doaj   +1 more source

SUCCESSFUL TREATMENT FOR ATYPICAL HEMOLYTIC UREMIC SYNDROME IN A PUERPERA

open access: yesОбщая реаниматология, 2016
Objective: to show the problems of differential diagnosis and treatment of atypical hemolytic-uremic syndrome in a 23-year-old patient.Results. Eculizumab (Soliris), (Alexon Pharmaceuticals Inc., USA) that is a glycosylated humanized monoclonal antibody ...
O. N. Ulitkina   +4 more
doaj   +1 more source

Complement Factor H‐Based Therapeutics: A Comprehensive Overview

open access: yesEuropean Journal of Immunology, Volume 56, Issue 7, July 2026.
Complement factor H is a central regulator of the complement system and thus a target for therapeutic intervention. In this review, we provide an overview of past and current factor H‐based therapeutic concepts and modalities to treat complement‐mediated diseases.
Sebastiaan M. W. R. Hamers   +2 more
wiley   +1 more source

Home - About - Disclaimer - Privacy